Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody

Susan Knox, Richard T. Hoppe, David Maloney, Iris Gibbs, Sherry Fowler, Carol Marquez, P. JoAnne Cornbleet, Ronald Levy

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Chimeric anti-CD4 monoclonal antibody was administered intravenously as a single dose to eight patients with mycosis fungoides. The dose was escalated throughout the study between patient groups, and individual patients received 50, 100, or 200 mg per dose. Seven of eight patients responded to treatment with an average freedom from progression of 25 weeks (range, 6 to 52 weeks). The treatment was well tolerated, and there was no clinical evidence of immunosuppression. Following treatment, there was significant suppression of peripheral blood CD4 counts in all patients for 1 to 22+ weeks. Only one patient made a very low titer human antichimeric antibody response. All but two patients made primary antibody and T-cell proliferative responses to a foreign antigen administered 24 hours after antibody infusion. However, there was generally marked, but temporary suppression of T-cell proliferative responses in vitro to phytohemagglutinin (PHA), tetanus toxoid, and normal donor lymphocytes. We conclude that at the dose levels studied, this antibody (1) had clinical efficacy against mycosis fungoides; (2) was well tolerated; (3) had a low level of immunogenicity; 14) decreased T-cell proliferative responses in vitro, and (5) did not induce tolerance to a foreign antigen.

Original languageEnglish (US)
Pages (from-to)893-899
Number of pages7
JournalBlood
Volume87
Issue number3
StatePublished - Feb 1 1996
Externally publishedYes

Fingerprint

Cutaneous T-Cell Lymphoma
T-cells
Monoclonal Antibodies
Antibodies
Mycosis Fungoides
Antigens
Tetanus Toxoid
Lymphocytes
T-Lymphocytes
Phytohemagglutinins
Therapeutics
Blood
CD4 Lymphocyte Count
Immunosuppression
Antibody Formation
Tissue Donors

ASJC Scopus subject areas

  • Hematology

Cite this

Knox, S., Hoppe, R. T., Maloney, D., Gibbs, I., Fowler, S., Marquez, C., ... Levy, R. (1996). Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood, 87(3), 893-899.

Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. / Knox, Susan; Hoppe, Richard T.; Maloney, David; Gibbs, Iris; Fowler, Sherry; Marquez, Carol; Cornbleet, P. JoAnne; Levy, Ronald.

In: Blood, Vol. 87, No. 3, 01.02.1996, p. 893-899.

Research output: Contribution to journalArticle

Knox, S, Hoppe, RT, Maloney, D, Gibbs, I, Fowler, S, Marquez, C, Cornbleet, PJ & Levy, R 1996, 'Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody', Blood, vol. 87, no. 3, pp. 893-899.
Knox S, Hoppe RT, Maloney D, Gibbs I, Fowler S, Marquez C et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood. 1996 Feb 1;87(3):893-899.
Knox, Susan ; Hoppe, Richard T. ; Maloney, David ; Gibbs, Iris ; Fowler, Sherry ; Marquez, Carol ; Cornbleet, P. JoAnne ; Levy, Ronald. / Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. In: Blood. 1996 ; Vol. 87, No. 3. pp. 893-899.
@article{30c20fc5fadb466a8f0e4687cf237796,
title = "Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody",
abstract = "Chimeric anti-CD4 monoclonal antibody was administered intravenously as a single dose to eight patients with mycosis fungoides. The dose was escalated throughout the study between patient groups, and individual patients received 50, 100, or 200 mg per dose. Seven of eight patients responded to treatment with an average freedom from progression of 25 weeks (range, 6 to 52 weeks). The treatment was well tolerated, and there was no clinical evidence of immunosuppression. Following treatment, there was significant suppression of peripheral blood CD4 counts in all patients for 1 to 22+ weeks. Only one patient made a very low titer human antichimeric antibody response. All but two patients made primary antibody and T-cell proliferative responses to a foreign antigen administered 24 hours after antibody infusion. However, there was generally marked, but temporary suppression of T-cell proliferative responses in vitro to phytohemagglutinin (PHA), tetanus toxoid, and normal donor lymphocytes. We conclude that at the dose levels studied, this antibody (1) had clinical efficacy against mycosis fungoides; (2) was well tolerated; (3) had a low level of immunogenicity; 14) decreased T-cell proliferative responses in vitro, and (5) did not induce tolerance to a foreign antigen.",
author = "Susan Knox and Hoppe, {Richard T.} and David Maloney and Iris Gibbs and Sherry Fowler and Carol Marquez and Cornbleet, {P. JoAnne} and Ronald Levy",
year = "1996",
month = "2",
day = "1",
language = "English (US)",
volume = "87",
pages = "893--899",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody

AU - Knox, Susan

AU - Hoppe, Richard T.

AU - Maloney, David

AU - Gibbs, Iris

AU - Fowler, Sherry

AU - Marquez, Carol

AU - Cornbleet, P. JoAnne

AU - Levy, Ronald

PY - 1996/2/1

Y1 - 1996/2/1

N2 - Chimeric anti-CD4 monoclonal antibody was administered intravenously as a single dose to eight patients with mycosis fungoides. The dose was escalated throughout the study between patient groups, and individual patients received 50, 100, or 200 mg per dose. Seven of eight patients responded to treatment with an average freedom from progression of 25 weeks (range, 6 to 52 weeks). The treatment was well tolerated, and there was no clinical evidence of immunosuppression. Following treatment, there was significant suppression of peripheral blood CD4 counts in all patients for 1 to 22+ weeks. Only one patient made a very low titer human antichimeric antibody response. All but two patients made primary antibody and T-cell proliferative responses to a foreign antigen administered 24 hours after antibody infusion. However, there was generally marked, but temporary suppression of T-cell proliferative responses in vitro to phytohemagglutinin (PHA), tetanus toxoid, and normal donor lymphocytes. We conclude that at the dose levels studied, this antibody (1) had clinical efficacy against mycosis fungoides; (2) was well tolerated; (3) had a low level of immunogenicity; 14) decreased T-cell proliferative responses in vitro, and (5) did not induce tolerance to a foreign antigen.

AB - Chimeric anti-CD4 monoclonal antibody was administered intravenously as a single dose to eight patients with mycosis fungoides. The dose was escalated throughout the study between patient groups, and individual patients received 50, 100, or 200 mg per dose. Seven of eight patients responded to treatment with an average freedom from progression of 25 weeks (range, 6 to 52 weeks). The treatment was well tolerated, and there was no clinical evidence of immunosuppression. Following treatment, there was significant suppression of peripheral blood CD4 counts in all patients for 1 to 22+ weeks. Only one patient made a very low titer human antichimeric antibody response. All but two patients made primary antibody and T-cell proliferative responses to a foreign antigen administered 24 hours after antibody infusion. However, there was generally marked, but temporary suppression of T-cell proliferative responses in vitro to phytohemagglutinin (PHA), tetanus toxoid, and normal donor lymphocytes. We conclude that at the dose levels studied, this antibody (1) had clinical efficacy against mycosis fungoides; (2) was well tolerated; (3) had a low level of immunogenicity; 14) decreased T-cell proliferative responses in vitro, and (5) did not induce tolerance to a foreign antigen.

UR - http://www.scopus.com/inward/record.url?scp=0030069871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030069871&partnerID=8YFLogxK

M3 - Article

C2 - 8562959

AN - SCOPUS:0030069871

VL - 87

SP - 893

EP - 899

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -